This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Medtronic will lay off 81 employees from a facility in Northridge, California, that works on diabetes devices, according to a state Worker Adjustment and Retraining Notification notice, filed Feb. 5. The cuts will go into effect on April 7. Medtronic does not plan to close the entire facility, but to restructure certain operations, according to a WARN letter. The af ...

Core Insights - Medtronic has launched a direct-to-consumer "Go Beyond" campaign, resulting in a significant increase in website traffic, with visits rising from approximately 50,000 to 2.5 million [1] - The company is focusing on scaling its Symplicity platform for renal denervation, targeting the 18 million patients in the U.S. with uncontrolled hypertension [2] - Medtronic's management highlighted strong growth in various product areas, including cardiovascular and diabetes segments, while reiterating financial guidance for fiscal 2026 and expectations for high single-digit adjusted EPS growth in fiscal 2027 [4][5] Product and Market Developments - The cardiovascular portfolio revenue grew 11% year-over-year, with a notable 80% growth in cardiac ablation systems (CAS), driven by pulsed field ablation (PFA) [12] - The MiniMed diabetes business reported a 15% increase in revenue, with significant growth attributed to international markets and new product launches [16] - Medtronic is scaling its Symplicity Spyral and Altaviva platforms, with early traction observed in patient referrals and physician training [6] Financial Performance - Medtronic reported revenue of $9.0 billion for the quarter, reflecting an 8.7% increase, with adjusted gross margin at 64.9% [5][17] - Adjusted operating profit reached $2.2 billion, with an adjusted operating margin of 24.1%, exceeding expectations [18] - The company maintained its fiscal 2026 organic revenue growth guidance of approximately 5.5% and adjusted EPS guidance of $5.62 to $5.66 [19] Regulatory and Technological Advancements - The Hugo robotic-assisted surgery system received FDA clearance for urologic procedures, marking the beginning of its U.S. launch [7] - The Stealth Access Surgical System for spinal procedures was also cleared by the FDA, integrating AI-powered planning and robotics [10][11] - Medtronic's Touch Surgery digital ecosystem installations surpassed 1,000 globally, showcasing a 20% sequential growth [8]